This brand name is authorized in Nigeria. It is also authorized in Australia, Austria, Canada, Cyprus, Finland, France, Germany, Hong Kong SAR China, Ireland, Israel, Malta, Netherlands, New Zealand, Singapore, South Africa, Tunisia, UK, United States.
The drug ZITHROMAX contains one active pharmaceutical ingredient (API):
1
|
UNII
5FD1131I7S - AZITHROMYCIN DIHYDRATE
|
Azithromycin is a macrolide antibiotic belonging to the azalide group. The molecule is constructed by adding a nitrogen atom to the lactone ring of erythromycin A. The mechanism of action of azithromycin is based upon the suppression of bacterial protein synthesis by means of binding to the ribosomal 50S sub-unit and inhibition of peptide translocation. |
|
This drug has been approved in Nigeria as follows:
Identifier | Form | Presentation | Description | Approval |
---|---|---|---|---|
04-1387 | Powder for suspension | Zithromax Powder for Oral Suspension PWD_F_SOL 200 mg/5 mL 15 mL (in HDPE bottle) | Powder for Oral Suspension. Dry powder which yields, on reconstitution with water, a white to off-white suspension containing the equivalent of 200 mg azithromycin per 5 mL | 30/11/2020 |
04-1388 | Capsule | Zithromax Capsules 250 mg CAP 250 mg 1 x 6's (in PVC blister) | Capsules for oral administration. Plain white No. 0 hard gelatin capsules containing Azithromycin dihydrate equivalent to 250 mg Azithromycin | 30/11/2020 |
04-6155 | Powder for injection | Zithromax IV 500 mg Injection INJ_PWD 500 mg 1 x 1's (in 10 mL Type I flint glass tubular vial) | Powder for solution for IV injection. Azithromycin is supplied in a lyophilized form under a vacuum in a 10 mL vial equivalent to 500 mg Azithromycin for IV administration. Upon reconstitution, Azithromycin powder yields a solution containing the equivalent of 100 mg Azithromycin per 1 mL | 24/06/2021 |
Below package inserts are available for further reading:
Document | Type | Information Source | |
---|---|---|---|
ZITHROMAX Capsule, hard | MPI, EU: SmPC | Medicines & Healthcare Products Regulatory Agency (GB) | |
ZITHROMAX Powder for solution for injection | MPI, US: SPL/PLR | FDA, National Drug Code (US) | |
ZITHROMAX Film-coated tablet / Powder for suspension | MPI, US: SPL/PLR | FDA, National Drug Code (US) |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
ATC Group | Classification | |
---|---|---|
J01FA10 | Azithromycin | J Antiinfectives for systemic use → J01 Antibacterials for systemic use → J01F Macrolides, lincosamides and streptogramins → J01FA Macrolides |
This drug has been assigned below unique identifiers within the countries it is being marketed:
Country | Identification scheme | Identifier(s) |
---|---|---|
AU | Pharmaceutical Benefits Scheme | 4115N, 5616N, 6221K, 8200N, 8201P, 8336R |
CA | Health Products and Food Branch | 02212021, 02223716, 02223724, 02239952 |
DE | Bundesinstitut für Arzneimittel und Medizinprodukte | 00010760, 02481966, 04678503, 07130987 |
FI | Lääkealan turvallisuus- ja kehittämiskeskus | 003742, 039776, 039784, 389452, 389460 |
FR | Base de données publique des médicaments | 62059468, 65740799, 67287098, 68175764 |
GB | Medicines & Healthcare Products Regulatory Agency | 139916, 164513, 19151, 19153, 19156, 19157, 19158, 375776, 381770, 381772, 381773 |
HK | Department of Health Drug Office | 36432, 44360, 44814, 45614 |
IE | Health Products Regulatory Authority | 59900, 59919, 91953, 91979 |
IL | מִשְׂרַד הַבְּרִיאוּת | 8658 |
MT | Medicines Authority | MA505/03901, MA505/03902, PI1438/09901A, PI770/13801A, PI908/07601C, PI908/07602A |
NG | Registered Drug Product Database | 04-1387, 04-1388, 04-6155 |
NL | Z-Index G-Standaard | 13810707 |
NL | Z-Index G-Standaard, PRK | 114995, 115002, 115010 |
NZ | Medicines and Medical Devices Safety Authority | 10223, 6161, 6162, 6163, 6164 |
SG | Health Sciences Authority | 07863P, 10720P, 10721P, 10911P, 12057P |
TN | Direction de la Pharmacie et du Médicament | 6043171, 9243053, 9243054, 9243055, 9243056 |
US | FDA, National Drug Code | 0069-0400, 0069-3051, 0069-3060, 0069-3070, 0069-3110, 0069-3120, 0069-3130, 0069-3140, 0069-3150, 0069-4061, 50090-0603, 61919-555, 70518-0336, 70518-0505 |
ZA | Health Products Regulatory Authority | 27/20.1.1/0279, 31/20.1.1/0045, 36/20.1.1/0190, A40/20.1.1/0102 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.